Tumor growth of PC9 xenografts with low-dose EGFR TKI + BEV therapy. Mice bearing PC9 xenografts were treated 10 mg/kg of gefitinib or gefitinib (10 mg/kg) +BEV (5 mg/kg), n=4-5. Data are presented as the mean \pm SD from week 0 (baseline) to week 2. *p < 0.05

S1 Fig

